PDCD1 and melanoma: While differential biology between RCC and melanoma, differences in activity between nivolumab and pembrolizumab, and differences in therapeutic duration may explain these discrepant observations, the addition of neoadjuvant PD-1 inhibition resulted in improved outcomes for patients with melanoma, supporting continued investigation of neoadjuvant ICI in RCC.